Longitudinal follow up of elevated pulmonary artery pressures in children with sickle cell disease
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Summary: Elevated pulmonary artery pressures (PAP) occur in approximately 30% of children with sickle cell disease. In adults, pulmonary hypertension is significantly associated with mortality. There are no data on the long term significance in children. Nineteen children with SS/Sß 0 thalassaemia had elevated PAP, defined as tricuspid regurgitant jet velocity (TRV) ≥2·5 m/s on screening echocardiograms. They were prospectively followed for 23 months (range 19–31 months). Patients with initial TRV ≥ 3 or TRV ≥ 2·5 m/s on repeat echocardiogram had cardiopulmonary evaluation and were offered treatment with hydroxyurea. Associated conditions like asthma and obstructive sleep apnea were treated. 18/19 patients had follow‐up echocardiograms. These showed normalization of TRV in 8 patients. Risk factors associated with persistent elevation were higher TRV on initial echocardiogram (P = 0·01), lower haemoglobin (P = 0·003) and lower oxygen saturation (P = 0·03). Five patients with persistently elevated PAP were treated with hydroxyurea. Mean right ventricular pressure dropped from 40·16 to 29·26 (P = 0·017) after 3–6 months and to 23·6 mmHg (P = 0·002) after 9–12 months on treatment. In conclusion (i) At borderline elevation of TRV there is intrapatient variability and echocardiograms should be repeated for confirmation. (ii) Elevated PAP are reversible in children with early detection and treatment with hydroxyurea.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322001 · Cited by 2,340 · cited 1×
“Hydroxyurea is a well established treatment for sickle cell disease and is used for many indications including frequent vasoocclusive crises, acute chest syndrome, priapism and severe anaemia (Charache et al, 1995).”
BackgroundCell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease
Reiter, C. D., Wang, X., Tanus-Santos, J. E., Hogg, N., Cannon, R. O., Schechter, A. N., & Gladwin, M. T. (2002) · Nature Medicine · doi:10.1038/nm1202-799 · Cited by 1,330 · cited 1×
“Impairment of NO bioavailability over decades leads to chronic vasoconstriction and mild pulmonary hypertension (Reiter et al, 2002; Gladwin et al, 2004; Morris et al, 2005; Rother et al, 2005).”
BackgroundPulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease
Gladwin, M. T., Sachdev, V., Jison, M. L., Shizukuda, Y., Plehn, J. F., Minter, K., Brown, B., Coles, W. A., Nichols, J. S., Ernst, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035477 · Cited by 1,325
Pulmonary hypertension in patients with sickle cell disease: a longitudinal study
Ataga, K. I., Moore, C. G., Jones, S., Olajide, O., Strayhorn, D., Hinderliter, A., & Orringer, E. P. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06110.x · Cited by 298 · cited 1×
“Similarly Ataga et al, found an increased risk of death (relative risk 9Æ24, 95% confidence interval 1Æ2–73Æ3) with a median follow up of 2Æ6 years (range 0Æ2–5Æ1 years) (Ataga et al, 2006).”
BackgroundA multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy
Bridges, K., Barabino, G., Brugnara, C., Cho, M., Christoph, G., Dover, G., Ewenstein, B., Golan, D., Guttmann, C., Hofrichter, J., et al. (1996) · Blood · doi:10.1182/blood.v88.12.4701.bloodjournal88124701 · Cited by 184 · cited 2×
“We decided to administer hydroxyurea to patients with moderate or persistently elevated pulmonary pressures as hydroxyurea not only decreases haemolysis, but also reduces red cell adhesion (Charache et al, 1992; Bridges et al, 1996; Hillery et al, 2000).”
BackgroundMethod
Cited by
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up
Steinberg, M. H., McCarthy, W. F., Castro, O., Ballas, S. K., Armstrong, F. D., Smith, W., Ataga, K., Swerdlow, P., Kutlar, A., DeCastro, L., et al. (2010) · American Journal of Hematology · doi:10.1002/ajh.21699 · Cited by 486
How I use hydroxyurea to treat young patients with sickle cell anemia
Ware, R. E. (2010) · Blood · doi:10.1182/blood-2009-04-146852 · Cited by 396
Kato, G. J., Hebbel, R. P., Steinberg, M. H., & Gladwin, M. T. (2009) · American Journal of Hematology · doi:10.1002/ajh.21475 · Cited by 349
Klings, E. S., Machado, R. F., Barst, R. J., Morris, C. R., Mubarak, K. K., Gordeuk, V. R., Kato, G. J., Ataga, K. I., Gibbs, J. S., Castro, O., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201401-0065st · Cited by 263
Hemodynamic Predictors of Mortality in Adults with Sickle Cell Disease
Mehari, A., Alam, S., Tian, X., Cuttica, M. J., Barnett, C. F., Miles, G., Xu, D., Seamon, C., Adams-Graves, P., Castro, O. L., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201207-1222oc · Cited by 135
“Last, supportive care of SCD with hydroxyurea or chronic transfusion has been more aggressively promoted in the last decade, and anecdotal evidence indicates that in some cases this may lead to better control of pulmonary arterial pressures (39, 40).”
Background
Metadata
- Authors
- Pashankar, F. D., Carbonella, J., Bazzy‐Asaad, A., & Friedman, A.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2009-01-27
- Volume
- 144
- Issue
- 5
- Pages
- 736-741
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2015491862
- Cited by
- 62
- References
- 5
- FWCI
- 3.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Longitudinal follow up of elevated pulmonary artery pressures in children with sickle cell disease. https://app.cochat.ai/papers/10.1111/j.1365-2141.2008.07501.x
- The paper
- Pashankar, F. D., Carbonella, J., Bazzy‐Asaad, A., & Friedman, A. (2009). Longitudinal follow up of elevated pulmonary artery pressures in children with sickle cell disease. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2008.07501.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.